Key points for designing and reporting Helicobacter pylori therapeutic trials: A personal view

Helicobacter

Volumn 16, Issue 5, 2011, Pages 346-355

  Calvet, Xavier ^a,b   Gisbert, Javier P ^b,c   Suarez, David ^d  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Clinical trials; Helicobacter pylori; Methodology

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DRUG CHOICE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; SAMPLE SIZE; STUDY DESIGN;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PATIENT SELECTION; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 80053045985     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2011.00890.x     Document Type: Article

References (51)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
2. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
3. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502.
4. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
5. Statistical annex: statistical aspects of clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut 1997;41 (Suppl 2):S19-23.
6. Technical annex: tests used to assess Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut 1997;41 (Suppl 2):S10-8.
7. Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut 1997;41 (Suppl 2):S1-9.
8. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
9. Van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
10. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86.
11. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG; International Stroke Trial Collaborative Group, European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:iii-X:1-173.
12. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM; Edusepsis Study Group. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009;180:861-6.
13. Hernán MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Manson JE, Robins JM. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008;19:766-79.
14. Suarez D, Haro JM, Novick D, Ochoa S. Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. J Clin Epidemiol 2008;61:525-30.
15. Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D, Windmeijer F. Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy 2006;5:11-25.
16. de Boer WA. Eradication therapy should be different for dyspeptic patients than for ulcer patients. Can J Gastroenterol 2003;17(Suppl B):41B-5B.
17. Huang JQ, Zheng GF, Hunt RH, Wong WM, Lam SK, Karlberg J, Wong BC. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 2005;11:2726-32.
18. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001;13:1303-7.
19. Taneike I, Nami A, O'Connor A, Fitzgerald N, Murphy P, Qasim A, O'Connor H, O'Morain C. Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? Aliment Pharmacol Ther 2009;30:784-90.
20. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547-50.
21. Gisbert JP, Luna M, Gómez B, Herrerías JM, Monés J, Castro-Fernández M, Sánchez-Pobre P, Cosme A, Olivares D, Pajares JM. Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. Aliment Pharmacol Ther 2006;23:713-9.
22. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005;100:2083-99.
23. Schoenfeld P, Cook D, Hamilton F, Laine L, Morgan D, Peterson W. An evidence-based approach to gastroenterology therapy. Evidence-Based Gastroenterology Steering Group. Gastroenterology 1998;114:1318-25.
24. Centre for evidence based medicine. EBM Tools: Critical Appraisal. Likelihood Ratios. URL:. 1 February 2009 (accessed 13 September 2009).
25. Arroyo MT, Forne M, de Argila CM, Feu F, Arenas J, et al. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter 2004;9:249-54.
26. Gisbert JP, Blanco M, Mateos JM, Fernández-Salazar L, Fernández-Bermejo M, Cantero J, Pajares JM. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999;44:2295-302.
27. Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, Richards ID, Dowell AC, Axon AT. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000;355:1665-9.
28. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004;20:1001-17.
29. Calvet X, Sanchez-Delgado J, Montserrat A, Lario S, Ramirez-Lazaro MJ, Quesada M, et al. Accuracy of diagnostic tests for Helicobacter pylori: a reappraisal. Clin Infect Dis 2009;48:1385-91.
30. Vaira D, Vakil N, Menegatti M, van't HB, Ricci C, Gatta L, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002;136:280-7.
31. Calvet X, Lario S, Ramirez-Lazaro MJ, Montserrat A, Quesada M, Reeves L, et al. Comparative accuracy of three monoclonal stool tests for diagnosis of H. pylori infection in dyspeptic patients. Clin Infect Dis 2010;50:323-8.
32. Calvet X, Sanfeliu I, Musulen E, Mas P, Dalmau B, Gil M, Bella MR, Campo R, Brullet E, Valero C, Puig J. Evaluation of Helicobacter pylori diagnostic methods in patients with liver cirrhosis. Aliment Pharmacol Ther 2002;16:1283-9.
33. 2 values. Aliment Pharmacol Ther 2006;23:275-80.
34. Gisbert JP, Pajares JM. Review article: Helicobacter pylori"rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
35. Lottspeich C, Schwarzer A, Panthel K, Koletzko S, Russmann H. Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic children. J Clin Microbiol 2007;45:1718-22.
36. Rimbara E, Fischbach LA, Graham DY; Medscape. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
37. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain C. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25.
38. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.
39. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7.
40. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-18.
41. CASP. Public Health Resource Unit. NHS. (accessed 25 August 2009).
42. Calvet X. What is the best first-line therapy for Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol 2008;5:606-7.
43. Random.org. URL: (accessed 30 January 2010).
44. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005;100:1696-701.
45. SealedEnvelope™. Power (Sample Size) Calculators. URL: (accessed 1 September 2009).
46. Sebille V, Bellissant E. Sequential methods and group sequential designs for comparative clinical trials. Fundam Clin Pharmacol 2003;17:505-16.
47. Exact Confidence Interval for a Proportion. URL: (accessed 24 September 2009).
48. Home PD. Techniques for ensuring that your next paper is quite unsuitable for publication. J R Coll Physicians Lond 1988;22:48-50.
49. Connor JT. Statistical graphics in AJG: save the ink for the information. Am J Gastroenterol 2009;104:1624-30.
50. Calvet X, Vergara M, Gisbert JP, Brullet E. Dual versus endoscopic monotherapy in bleeding peptic ulcers. Am J Gastroenterol 2007;102:1826-7.
51. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006;295:1172-4.